SCHEMBL540965

SCHEMBL540965

O=C(Nc1ccc(Cl)cc1)Nc1nc2ccccc2s1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.79
RAB9A P51151 8/20 0.79
NPC1 O15118 7/20 0.79
MEN1 O00255 5/20 0.79
KMT2A Q03164 5/20 0.79
GAA P10253 3/20 0.79
NFKB1 P19838 1/20 0.79
NFKB2 Q00653 1/20 0.79
RELA Q04206 1/20 0.79
POLB P06746 2/20 0.64
LMNA P02545 1/20 0.64
NPSR1 Q6W5P4 1/20 0.64
KDM4E B2RXH2 2/20 0.63
ALOX5 P09917 1/20 0.63
EPHX2 P34913 1/20 0.63
RECQL P46063 1/20 0.63
SMN1; SMN2 Q16637 5/20 0.61
HPGD P15428 1/20 0.61
DHODH Q02127 1/20 0.60
FFAR2 O15552 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1143751 0.88 NPC1 (1.00) MAPTRAB9ANPC1MEN1KMT2A
Hydrochloric Acid SCHEMBL28640786 0.87 NPC1 (0.97) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL32674581 0.87 NPC1 (0.84) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL24104691 0.86 KDM4E (0.74) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL4922739 0.86 NPC1 (0.79) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL18851598 0.86 KDM4E (0.63) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL30136366 0.86 KDM4E (0.74) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL2245925 0.86 NPC1 (0.79) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL6225459 0.85 MAPT (0.73) MAPTRAB9ANPC1MEN1KMT2A
SCHEMBL31206306 0.85 MAPT (0.73) MAPTRAB9ANPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240199562-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Institut National de la Santé et de la Recherche Médicale (FR) 2024-06-20 US claimed
EP-4322944-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Centre National de la Recherche Scientifique (FR) 2024-02-21 EP claimed
WO-2022219123-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-20 WO claimed
CN-113271941-B Urea derivatives for the treatment and/or prophylaxis of cancer 法国国家科学研究中心 2024-09-20 CN disclosed
US-20240199562-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Institut National de la Santé et de la Recherche Médicale (FR) 2024-06-20 US disclosed
EP-4322944-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA Centre National de la Recherche Scientifique (FR) 2024-02-21 EP disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 US disclosed
US-11731985-B2 Compositions and methods for treating cancer HB THERAPEUTICS INC. (US) 2023-08-22 US disclosed
WO-2022219123-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2022-10-20 WO disclosed
US-20210380547-A1 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2021-12-09 US disclosed
CN-113271941-A Urea derivatives for the treatment and/or prevention of cancer 法国国家科学研究中心 2021-08-17 CN disclosed
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2021-04-22 US disclosed
WO-2020079184-A2 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2020-04-23 WO disclosed
WO-2019217509-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER HB THERAPEUTICS INC. (US) 2019-11-14 WO disclosed
US-20180312493-A1 Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor CENTRE FOR DRUG RESEARCH AND DEVELOPMENT (CA) 2018-11-01 US disclosed
WO-2017075694-A1 ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR SIMON FRASER UNIVERSITY (CA) 2017-05-11 WO disclosed
WO-2017075694-A1 ANTIBIOTIC COMPOUNDS, PHARMACEUTICAL FORMULATIONS THEREOF AND METHODS AND USES THEREFOR SIMON FRASER UNIVERSITY (CA) 2017-05-11 WO disclosed
EP-2414346-A1 AUTOTAXIN INHIBITORS Merck Patent GmbH (DE) 2012-02-08 EP disclosed
WO-2010112124-A1 AUTOTAXIN INHIBITORS MERCK PATENT GMBH (DE) 2010-10-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11731985-B2 Compositions and methods for treating cancer VHL, TP53, NUDT1 MAPT 1476/4885RAB9A 3882/4885NPC1 424/4885
US-20210115064-A1 COMPOSITIONS AND METHODS FOR TREATING CANCER VHL, TP53, NUDT1 MAPT 1587/4885RAB9A 4161/4885NPC1 749/4885
US-20240199562-A1 UREA DERIVATIVES FOR TREATING UVEAL MELANOMA UACA, SLC14A1, MITF MAPT 409/4885RAB9A 1206/4885NPC1 2159/4885
US-20210380547-A1 UREA DERIVATIVES FOR TREATING AND/OR PREVENTING CANCER CXCR1, CXCR2, CXCR6 MAPT 3890/4885RAB9A 1386/4885NPC1 331/4885
US-20180312493-A1 Antibiotic Compounds, Pharmaceutical Formulations Thereof And Methods And Uses Therefor UGT1A8, CYP2C8, CXCL8 MAPT 3944/4885RAB9A 663/4885NPC1 52/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.